The Cancer Anorexia-Cachexia Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cancer Anorexia-Cachexia Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Cancer Anorexia-Cachexia Syndrome by 37 companies/universities/institutes. The top development phase for Cancer Anorexia-Cachexia Syndrome is preclinical with 14 drugs in that stage. The Cancer Anorexia-Cachexia Syndrome pipeline has 36 drugs in development by companies and two by universities/ institutes. Some of the companies in the Cancer Anorexia-Cachexia Syndrome pipeline products market are: Byomass, Yinuoke and Hope Medicine.
The key targets in the Cancer Anorexia-Cachexia Syndrome pipeline products market include Growth/Differentiation Factor 15, Growth Hormone Secretagogue Receptor Type 1, and Cannabinoid Receptor 2.
The key mechanisms of action in the Cancer Anorexia-Cachexia Syndrome pipeline product include Growth/Differentiation Factor 15 Inhibitor with seven drugs in Phase II. The Cancer Anorexia-Cachexia Syndrome pipeline products include four routes of administration with the top ROA being Oral and eight key molecule types in the Cancer Anorexia-Cachexia Syndrome pipeline products market including Small Molecule, and Monoclonal Antibody.
Cancer Anorexia-Cachexia Syndrome overview
Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according to the tumor site.
For a complete picture of Cancer Anorexia-Cachexia Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
